Johnson & Johnson Shares Hold Steady After Q1 Earnings, Analysts Optimistic About Future
Johnson & Johnson Shares Hold Steady After Q1 Earnings, Analysts Optimistic About Future
On Tuesday, Johnson & Johnson (NYSE:JNJ) reported first-quarter adjusted EPS of $2.71, up 12.4% year over year, beating the consensus of $2.64.
周二，强生公司（纽约证券交易所代码：JNJ）公布的第一季度调整后每股收益为2.71美元，同比增长12.4％，超过市场普遍的2.64美元。
The pharma giant reported sales of $21.38 billion, up 2.3% year over year, almost in line with the consensus of $21.39 billion. Operational growth was 3.9%, and adjusted operational growth was 4.0%.
这家制药巨头报告的销售额为213.8亿美元，同比增长2.3％，几乎与213.9亿美元的共识持平。运营增长3.9％，调整后的运营增长4.0％。
After good earnings results, Cantor Fitzgerald remains positive on Johnson & Johnson's stock.
在取得良好的盈利业绩之后，坎托·菲茨杰拉德对强生公司的股票仍然持乐观态度。
The analyst writes that numerous positive data releases and approvals for new uses of existing drugs are anticipated to boost Johnson & Johnson stock.
这位分析师写道，大量积极的数据发布和现有药物新用途的批准预计将提振强生公司的股票。
Cantor notes that the market is undervaluing the potential peak sales of Taris, Carvykti, Mariposa, nipocalimab, JNJ-2113, and other products.
坎托尔指出，市场低估了Taris、Carvykti、Mariposa、nipocalimab、JNJ-2113 和其他产品的潜在峰值销售额。
Additionally, the pharma/medtech giant aims to lead in Innovative Medicines and MedTech, seeking to become the top player in these fields.
此外，这家制药/医疗科技巨头的目标是在创新药物和医疗技术领域处于领先地位，寻求成为这些领域的顶级参与者。
While the market sees Johnson & Johnson as strong in its sectors, it doesn't yet perceive it as the best.
尽管市场认为强生公司在其行业中表现强劲，但尚未将其视为最好的。
Cantor maintains the Overweight rating with a price target of $215.
坎托维持增持评级，目标股价为215美元。
Also Read: Johnson & Johnson's Carvykti Stands Ahead Of Bristol Myers' Rival Blood Cancer Therapy With FDA Approval For Wider Population.
另请阅读：强生公司的Carvykti领先于布里斯托尔·迈尔斯的竞争对手血癌疗法，获得美国食品药品管理局的批准，适用于更多人群。
Goldman Sachs noted several variances in pharmaceutical performance compared to their expectations. Stelara fell short by 5% compared to GS estimates and 4% compared to consensus. Xarelto was notably below expectations, with a difference of 9% and 7%, respectively.
高盛指出，与预期相比，制药业绩存在一些差异。与GS的估计相比，Stelara下跌了5％，与共识相比下跌了4％。Xarelto明显低于预期，差异分别为9％和7％。
However, Tremfya showed a slight upside, surpassing expectations by 3% and 2%.
但是，Tremfya略有上涨，比预期高出3％和2％。
The Multiple myeloma franchise performed well in the oncology sector, with Darzalex achieving a strong 22% year-on-year growth.
多发性骨髓瘤特许经营权在肿瘤学领域表现良好，Darzalex实现了22％的强劲同比增长。
Carvykti, however, was disappointed with flat sequential growth and a decline of 16% compared to GS estimates and 13% compared to consensus. Management attributed this to the phasing of orders, expecting order trends to improve, especially with the recent label expansion.
但是，Carvykti对连续增长持平感到失望，与GS的估计相比下降了16％，与市场预期相比下降了13％。管理层将此归因于订单的分阶段，预计订单趋势将有所改善，尤其是在最近的品牌扩张中。
Price Action: JNJ shares are down 0.13% at $144.26 on the last check Wednesday.
价格走势：在周三的最后一次支票中，JNJ股价下跌0.13％，至144.26美元。
Photo via Wikimedia Commons
照片来自维基共享资源